- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04415294
Flicker App for Minimal Hepatic Encephalopathy
Evaluating a Novel, Self-administered Device ("Flicker-App") That Measures Critical Flicker Frequency as a Test for Minimal Hepatic Encephalopathy in Cirrhosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
SA 1. Determine whether cirrhotic patients (n=75) can self-administer the Flicker-App in clinic supervised by a research assistant and calculate the level of agreement between the CFF determined by the Flicker-App, the CFF determined by the "gold-standard" FFS device, and the test scores on the EncephalApp Stroop test.
SA 2. Determine whether cirrhotic patients (n=75) can self-administer the Flicker-App at home, including daily measurements over 1 week and weekly measurements over 6 weeks, and calculate the adherence to this protocol and the variability of these CFF measurements.
SA3. Make any necessary software or hardware adjustments to the Flicker-App to facilitate and simplify its self-administration by patients based on structured interview-questionnaires with the study participants and with clinical Gastroenterologists/Hepatologists
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Michael Yacoub
- Phone Number: 2067443402
- Email: yacoum@washington.medicine.edu
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- University of Washington Medical Center
-
Contact:
- Michael Yacoub
- Phone Number: 206-744-3402
- Email: yacoum@medicine.washington.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Cirrhosis (standard criteria)
- Chronic liver disease
Exclusion Criteria:
- Grade III or IV hepatic encephalopathy
- Mini-mental state examination score ≤25 (suggestive of dementia)
- alcohol or illicit drug use within 3 months
- current use of benzodiazepines
- antiepileptics or psychotropic drugs
- color blindness
- severe vision impairment (blindness, macular degeneration).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CFF Agreement
Time Frame: 1 day
|
Level of agreement between Flicker App CFF and gold-standard device
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: George N Ioannou, MD, MS, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004521
- R21DK117431 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Consorci Sanitari de l'Alt Penedès i GarrafWithdrawn
-
Ain Shams UniversityCompletedMinimal Hepatic Encephalopathy
-
Mansoura UniversityCompletedMinimal Hepatic EncephalopathyEgypt
-
Shanghai Changzheng HospitalEnrolling by invitationHepatic Encephalopathy | Covert Hepatic EncephalopathyChina
Clinical Trials on Critical flicker frequency
-
University Hospital, ToulouseCompleted
-
University of BariCompletedHepatic Encephalopathy | Minimal Brain DysfunctionItaly
-
The First Affiliated Hospital of Shanxi Medical...Shanxi Medical UniversityCompletedSleep Quality | Sleep Duration | Sleep Onset LatencyChina
-
Medical University of ViennaCompletedOcular Physiology | Retina | Blood Flow VelocityAustria
-
Medical University of ViennaWithdrawnAmblyopia | Regional Blood FlowAustria
-
LKC Technologies, Inc.Unknown
-
National Taiwan University HospitalRecruiting
-
Patrick J. ThoralLeiden University Medical CenterRecruitingCritical IllnessNetherlands
-
National Taiwan University HospitalRecruiting
-
University of British ColumbiaUnknownMyocardial Infarction | Heart FailureCanada